• Cardinal Health reported past third-quarter 2026 results showing higher sales of US$60,940 million but lower net income of US$399 million, alongside a pre-tax goodwill impairment of US$184 million in its Navista & ION unit and completion of a US$1.73 billion share repurchase program.
• The Board’s decision to raise the quarterly dividend to US$0.5158 per share, even as earnings softened and impairments were taken, underscores management’s confidence in cash generation and the ongoing shift toward higher-value services and specialty operations.
• Now we’ll examine how the dividend increase, alongside raised earnings guidance, interacts with Cardinal Health’s existing long-term investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to believe its scale in pharmaceutical distribution and growing specialty and services businesses can offset thin margins, regulatory pressure and customer concentration. The latest quarter showed strong sales but weaker earnings, plus a goodwill impairment in Navista & ION; taken together with the dividend increase and higher guidance, these do not materially alter the near term catalyst of specialty expansion, nor the key risk around regulation and reimbursement pressure.

The most relevant recent announcement is the Board’s decision to lift the quarterly dividend to US$0.5158 per share, even as Q3 net income declined and an impairment was recognized. For income focused investors, that higher payout, funded from capital surplus, sits alongside buybacks completed at US$1,733.96 million and raised full year adjusted EPS guidance, and all of this now needs to be weighed against tariff and broader regulatory risks.

However, investors should also be aware that tighter reimbursement policies and competitive bidding in at home care could...

Cardinal Health's narrative projects $317.9 billion revenue and $2.6 billion earnings by 2029. This requires 9.1% yearly revenue growth and about a $0.9 billion earnings increase from $1.7 billion today.

Uncover how Cardinal Health's forecasts yield a $248.27 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see Cardinal Health’s fair value between US$245.27 and US$466.19 per share, underlining how far opinions can spread. Set against this, the risk that regulation and tariffs compress already thin margins may influence how you interpret those very different valuation views and encourages you to consider multiple angles on the stock.

Explore 3 other fair value estimates on Cardinal Health - why the stock might be worth just $245.27!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.